poisar

Stock

Revolution Medicines, Inc. RVMD

$220.48+2.47%

Overview

RVMD market data

Price History

RVMD price chart · 1M
O
221.32
H
224.18
L
216.27
C
220.48
Vol
123,159.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$221.32
Previous Close
$215.16
Day High
$224.18
Day Low
$216.27
52 Week High
$224.18
52 Week Low
$139.25
7 Day Return
+4.07%
30 Day Return
+19.93%
90 Day Return
+39.91%
1 Year Return
+56.86%
Daily Notional Volume
$27.2M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$5.95
Diluted earnings per share over the trailing twelve months.
Beta
1.41
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-2,833.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$35.42 – $220.34
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $43.2B · P/B 9.44 · P/S 3,733.66.

Company News

10 captured
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock SurgesBenzinga · Aug 27, 2026, 5:13 PM
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer DrugBenzinga · Aug 27, 2026, 3:44 PM
Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival ResultsBenzinga · Aug 27, 2026, 3:08 PM
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260Benzinga · Aug 27, 2026, 2:42 PM
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251Benzinga · Aug 27, 2026, 2:30 PM
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $225Benzinga · Aug 27, 2026, 1:25 PM
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239Benzinga · Aug 27, 2026, 1:02 PM
Top 3 Health Care Stocks That May Keep You Up At Night In Q3Benzinga · Aug 27, 2026, 12:46 PM
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320Benzinga · Aug 27, 2026, 12:43 PM
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $280Benzinga · Aug 27, 2026, 12:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock